efalizumab
Sign in to saveAlso known as Anti-Cd11A, hu1124, antiCD11 alpha, anti alphaL integrin
Efalizumab (brand name Raptiva) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. It is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009.
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 461092863
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- CD11a
- Drug.tradename
- Raptiva
- Drug.routes_of_administration
- Subcutaneous
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AG02
- Drug.CAS_number
- 214745-43-4
- Drug.DrugBank
- DB00095
- Drug.ChemSpiderID
- none
- Drug.UNII
- XX2MN88N5D
- Drug.ChEMBL
- 1201575
- Drug.melting_point
- 66
via Wikipedia infobox
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Efalizumab (brand name Raptiva) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. It is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009.
Known side effects include bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy (PML), a brain infection caused by reactivation of latent JC virus infection. Four cases of PML were reported in plaque psoriasis patients, an incidence of approximately one in 500 treated patients.
Excerpted from Wikipedia’s “efalizumab” article, available under the CC BY-SA 4.0 licence.